- Home
- MCBS vs PSNL Comparison
MCBS vs PSNL Comparison
Compare MCBS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCBS | PSNL |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.1M | 746.8M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MCBS | PSNL |
|---|---|---|
| Price | $26.54 | $7.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $31.00 | $10.71 |
| AVG Volume (30 Days) | 45.9K | ★ 1.4M |
| Earning Date | 01-20-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.77% | N/A |
| EPS Growth | ★ 11.15 | N/A |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $147,349,000.00 | $69,103,000.00 |
| Revenue This Year | $13.89 | N/A |
| Revenue Next Year | $33.10 | $20.33 |
| P/E Ratio | $10.25 | ★ N/A |
| Revenue Growth | ★ 8.69 | N/A |
| 52 Week Low | $24.24 | $2.83 |
| 52 Week High | $34.91 | $11.40 |
Technical Indicators
Market Signals| Indicator | MCBS | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 40.16 | 41.71 |
| Support Level | $27.01 | $7.88 |
| Resistance Level | $27.08 | $9.10 |
| Average True Range (ATR) | 0.56 | 0.47 |
| MACD | -0.24 | -0.10 |
| Stochastic Oscillator | 4.36 | 16.16 |
Price Performance
Historical ComparisonAbout MCBS MetroCity Bankshares Inc.
MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.